WCLC 2025 - Posters & ePosters-P3.12.52 Aumolertinib Plus Anlotinib in Advanced EGFR-Mutant NSCLC With TP53 Co-Mutation: A Single-Arm, Phase II Study

P3.12.52 Aumolertinib Plus Anlotinib in Advanced EGFR-Mutant NSCLC With TP53 Co-Mutation: A Single-Arm, Phase II Study

Asset Subtitle

Zhansheng Jiang

Meta Tag

Speaker Zhansheng Jiang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy